RESEARCH MONOGRAPH · KDC-MN-357

Loratadine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

82/100

Reliable peripherally-selective H1 blocker, mechanistically the desloratadine metabolite is whats doing most of the work

Loratadine is the second-generation H1 blocker that broke through commercially in the 1990s and has been a workhorse antihistamine ever since. The selectivity is good (much less CNS penetration than first-generation H1 blockers, minimal anticholinergic activity), and the once-daily dosing is convenient because of the long half-life of the active metabolite.

The metabolism story is where the pharmacology gets interesting. Loratadine itself has H1 affinity but the major active metabolite, desloratadine (formed via CYP3A4 and CYP2D6), is significantly more potent and has a longer half-life. Which means a meaningful fraction of loratadine's clinical effect is actually desloratadine effect, and CYP interactions matter more than the marketing acknowledges. Desloratadine became its own marketed product (Clarinex) partly to bypass this pharmacokinetic complication.

From a research standpoint, the H1 selectivity is solid but not as clean as fexofenadine, and there's some weak H4 receptor activity at higher concentrations that may or may not matter depending on the experimental question. The Thurmond lab work on H4 receptors is informative if you're trying to dissect histamine receptor subtype contributions to inflammation and pruritus.

For research use, loratadine and desloratadine are useful as clinically validated peripheral H1 probes. The pharmacokinetics are well-characterized, the formulation chemistry is straightforward, and reference standards are everywhere.

Sourcing is excellent. Standard small molecule, widely available, USP reference standards exist, OTC formulations are pharmacopoeia grade. Research-grade is cheap.

What we like is the reliability. Loratadine works consistently across populations, the side effect profile is genuinely mild, and the drug interaction profile (CYP3A4-mediated mainly) is well-mapped.

What we dont love is the marketing of loratadine as non-sedating when the reality is more like minimally sedating in most people. Real but milder than first-gen, not zero. Also the CYP3A4 dependence means co-administration with strong CYP3A4 inhibitors (some macrolides, azole antifungals) can produce supratherapeutic exposures.

Honestly compared to cetirizine and fexofenadine, loratadine is the slightly older sibling in this category. Still works fine, still cheap, still well-characterized. Just not the first choice for a research probe if you have alternatives.

Evidence: 88
Mechanism: 82
Reliability: 85
Safety: 88
Sourcing: 92
Value: 90
Signal: 60
Staying power: 72

Plain-language summary Intrigue 44 / 100

Loratadine, sold as Claritin, is a second-generation antihistamine that is technically a prodrug: most of its clinical effect comes from the active metabolite desloratadine generated by the liver. Like cetirizine it stays largely peripheral, producing allergy relief without significant sedation or anticholinergic effects. It has somewhat lower H1 affinity than cetirizine but a longer duration of action, supporting dosing. The choice between loratadine, cetirizine, and fexofenadine is largely a matter of individual tolerability and onset preference. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Second-generation H1 antihistamine (peripheral)

A piperidine second-generation H1 antihistamine; a non-sedating allergy medication and the prodrug of desloratadine.

Abstract

Loratadine (ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate; CAS 79794-75-5; molecular formula C22H23ClN2O2; molecular weight 382.88) is a piperidine second-generation H1 antihistamine developed at Schering-Plough and approved by the FDA in 1993 (Claritin). H1 affinity is approximately 100 nM, lower than cetirizine but with similar peripheral selectivity (minimal CNS penetration). The principal active species is the metabolite desloratadine (formed via CYP3A4 and CYP2D6), which has higher H1 affinity (approximately 0.4 nM) and longer half-life; desloratadine is marketed separately as Clarinex. Plasma half-life of loratadine is approximately 8 hours; desloratadine half-life is approximately 27 hours. Approved indications: allergic rhinitis, urticaria. Sedation incidence is approximately 8 percent (similar to placebo in most trials), the lowest of the second-generation antihistamines. Used as the canonical non-sedating H1 antihistamine in research.

Mechanism of action

Second-generation H1 antagonist with peripheral selectivity; principal active species is metabolite desloratadine (higher affinity and longer half-life than parent).

Reported research dose ranges

Clinical 10 mg in the published literature.

References

Haria M, et al. Loratadine: a reappraisal. Drugs 1994.
Simons FE. Advances in H1-antihistamines. N Engl J Med 2004.
DuBuske LM. Pharmacokinetics of desloratadine, the active metabolite of loratadine. Allergy 2002.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-357

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Loratadine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs